Bausch + Lomb (Abbreviated New Drug Application) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • M&A

  • Financing Rounds
  • 1

Bausch + Lomb (Abbreviated New Drug Application) General Information

Description

Rights to an abbreviated new drug application (ANDA). The ANDA rights concern Nystatin Oral suspension, a treatment for candidiasis in the oral cavity.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • 1400 North Goodman Street
  • Rochester, NY 14609
  • United States
Primary Industry
Pharmaceuticals
Acquirer
Hi-Tech Pharmaceuticals
Vertical(s)
Life Sciences
Corporate Office
  • 1400 North Goodman Street
  • Rochester, NY 14609
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Bausch + Lomb (Abbreviated New Drug Application) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Bausch + Lomb (Abbreviated New Drug Application)‘s full profile, request access.

Request a free trial

Bausch + Lomb (Abbreviated New Drug Application) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Bausch + Lomb (Abbreviated New Drug Application)‘s full profile, request access.

Request a free trial

Bausch + Lomb (Abbreviated New Drug Application) FAQs

  • Where is Bausch + Lomb (Abbreviated New Drug Application) headquartered?

    Bausch + Lomb (Abbreviated New Drug Application) is headquartered in Rochester, NY.

  • What industry is Bausch + Lomb (Abbreviated New Drug Application) in?

    Bausch + Lomb (Abbreviated New Drug Application)’s primary industry is Pharmaceuticals.

  • Is Bausch + Lomb (Abbreviated New Drug Application) a private or public company?

    Bausch + Lomb (Abbreviated New Drug Application) is a Private company.

  • What is Bausch + Lomb (Abbreviated New Drug Application)’s current revenue?

    The current revenue for Bausch + Lomb (Abbreviated New Drug Application) is .

  • Who are Bausch + Lomb (Abbreviated New Drug Application)’s investors?

    Bausch + Lomb has invested in Bausch + Lomb (Abbreviated New Drug Application).

  • When was Bausch + Lomb (Abbreviated New Drug Application) acquired?

    Bausch + Lomb (Abbreviated New Drug Application) was acquired on 21-Mar-2011.

  • Who acquired Bausch + Lomb (Abbreviated New Drug Application)?

    Bausch + Lomb (Abbreviated New Drug Application) was acquired by Hi-Tech Pharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »